PAVmed Inc (NASDAQ: PAVM)’s stock price has plunge by -1.67relation to previous closing price of 0.22. Nevertheless, the company has seen a -7.92% plunge in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-15 that PAVmed Inc. (NASDAQ:PAVM ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Michael Parks – Vice President of Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Executive Vice President and Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Ed Woo – Ascendiant Capital Anthony Vendetti – Maxim Group Operator Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode.

Is It Worth Investing in PAVmed Inc (NASDAQ: PAVM) Right Now?

, and the 36-month beta value for PAVM is at 0.72. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price suggested by analysts for PAVM is $2.63, which is $2.4 above the current market price. The public float for PAVM is 108.31M, and currently, shorts hold a 3.33% of that float. The average trading volume for PAVM on November 17, 2023 was 656.99K shares.

PAVM’s Market Performance

The stock of PAVmed Inc (PAVM) has seen a -7.92% decrease in the past week, with a -23.42% drop in the past month, and a -5.07% fall in the past quarter. The volatility ratio for the week is 10.77%, and the volatility levels for the past 30 days are at 12.40% for PAVM. The simple moving average for the last 20 days is -14.98% for PAVM stock, with a simple moving average of -43.15% for the last 200 days.

Analysts’ Opinion of PAVM

Many brokerage firms have already submitted their reports for PAVM stocks, with Cantor Fitzgerald repeating the rating for PAVM by listing it as a “Overweight.” The predicted price for PAVM in the upcoming period, according to Cantor Fitzgerald is $8 based on the research report published on March 30, 2021 of the previous year 2021.

PAVM Trading at -26.29% from the 50-Day Moving Average

After a stumble in the market that brought PAVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.72% of loss for the given period.

Volatility was left at 12.40%, however, over the last 30 days, the volatility rate increased by 10.77%, as shares sank -30.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.53% lower at present.

During the last 5 trading sessions, PAVM fell by -11.05%, which changed the moving average for the period of 200-days by -59.62% in comparison to the 20-day moving average, which settled at $0.2512. In addition, PAVmed Inc saw -54.71% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PAVM starting from Glennon Michael J, who purchase 100,000 shares at the price of $0.62 back on Dec 07. After this action, Glennon Michael J now owns 250,000 shares of PAVmed Inc, valued at $62,320 using the latest closing price.

Glennon Michael J, the Director of PAVmed Inc, purchase 88,000 shares at $0.64 during a trade that took place back on Dec 06, which means that Glennon Michael J is holding 150,000 shares at $56,082 based on the most recent closing price.

Stock Fundamentals for PAVM

Current profitability levels for the company are sitting at:

The net margin for PAVmed Inc stands at -23602.92. The total capital return value is set at -143.20, while invested capital returns managed to touch -330.60. Equity return is now at value -754.31, with -123.33 for asset returns.

When we switch over and look at the enterprise to sales, we see a ratio of 15.57, with the company’s debt to enterprise value settled at 0.58. The receivables turnover for the company is 3.47 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.


In conclusion, PAVmed Inc (PAVM) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.